Literature DB >> 25788851

Multiple sclerosis; a disease of reproductive-aged women and the dilemma involving contraceptive methods.

Esengül Türkyılmaz1, Melahat Yıldırım1, Ayşe Filiz Yavuz Avşar2.   

Abstract

Multiple sclerosis (MS) is an autoimmune disorder characterized by chronic inflammation in the central nerves system. Because the disease predominantly affects women of reproductive ages, having knowledge about contraception options for MS patients can make clinicians provide better counseling. Although most contraceptive methods are generally accepted as safe and effective in MS patients, recent studies have raised questions about their potential adverse effects on the disease. The use of contraceptive methods to avoid unintended pregnancies is crucial in MS patients, particularly during the relapse phase of the disease or the time when the disease is not completely under control. This review investigates the contraception options and their effects on female MS patients. Providing appropriate contraception options to multiple sclerosis patients will be one of the most challenging issues for clinicians to deal with. Recent studies have raised questions that the use of hormonal contraceptives may at least partly contribute to the rise in incidence of MS in women. This review investigates the contraception options and their effects on female MS patients.

Entities:  

Keywords:  Multiple Sclerosis; contraception; contraceptives

Year:  2015        PMID: 25788851      PMCID: PMC4358313          DOI: 10.5152/jtgga.2015.15186

Source DB:  PubMed          Journal:  J Turk Ger Gynecol Assoc        ISSN: 1309-0380


  26 in total

1.  Estrogen treatment down-regulates TNF-alpha production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice.

Authors:  A Ito; B F Bebo; A Matejuk; A Zamora; M Silverman; A Fyfe-Johnson; H Offner
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

Review 2.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

Authors:  A W Griffioen; G Molema
Journal:  Pharmacol Rev       Date:  2000-06       Impact factor: 25.468

Review 3.  The intrauterine device, pelvic inflammatory disease, and infertility: the confusion between hypothesis and knowledge.

Authors:  D A Grimes
Journal:  Fertil Steril       Date:  1992-10       Impact factor: 7.329

4.  Recent use of oral contraceptives and the risk of multiple sclerosis.

Authors:  Alvaro Alonso; Susan S Jick; Michael J Olek; Alberto Ascherio; Hershel Jick; Miguel A Hernán
Journal:  Arch Neurol       Date:  2005-09

5.  17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.

Authors:  A Matejuk; K Adlard; A Zamora; M Silverman; A A Vandenbark; H Offner
Journal:  J Neurosci Res       Date:  2001-09-15       Impact factor: 4.164

6.  17beta-Estradiol inhibits class II major histocompatibility complex (MHC) expression: influence on histone modifications and cbp recruitment to the class II MHC promoter.

Authors:  Jill Adamski; Zhendong Ma; Susan Nozell; Etty N Benveniste
Journal:  Mol Endocrinol       Date:  2004-05-13

7.  The Oxford-Family Planning Association contraceptive study.

Authors:  M P Vessey; M Lawless
Journal:  Clin Obstet Gynaecol       Date:  1984-12

8.  Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis.

Authors:  Kerstin Hellwig; Sebastian Schimrigk; Christian Beste; Thomas Muller; Ralf Gold
Journal:  Eur Neurol       Date:  2008-11-28       Impact factor: 1.710

9.  The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination.

Authors:  Rashad Hussain; Abdel M Ghoumari; Bartosz Bielecki; Jérôme Steibel; Nelly Boehm; Philippe Liere; Wendy B Macklin; Narender Kumar; René Habert; Sakina Mhaouty-Kodja; François Tronche; Regine Sitruk-Ware; Michael Schumacher; M Said Ghandour
Journal:  Brain       Date:  2013-01       Impact factor: 13.501

10.  The intrauterine device and pelvic inflammatory disease revisited: new results from the Women's Health Study.

Authors:  N C Lee; G L Rubin; R Borucki
Journal:  Obstet Gynecol       Date:  1988-07       Impact factor: 7.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.